ARS Pharmaceuticals OptumRx Cigna
- has announced a significant milestone in allergy care with the inclusion of their innovative epinephrine nasal spray, neffy®, on the national formularies of leading healthcare providers Cigna Healthcare,...
- Millions of patients nationwide now have improved access to neffy through their commercial insurance, thanks to coverage from leading pharmaceutical benefit managers and health plans.
- This announcement underscores the critical demand for a nasal spray epinephrine option within the severe allergy community.
Expanded Access to Epinephrine Nasal Spray neffy Boosts Allergy Care for Millions
Table of Contents
- Expanded Access to Epinephrine Nasal Spray neffy Boosts Allergy Care for Millions
- The Critical Demand for Epinephrine Nasal Spray
- Improved Coverage for Severe Allergic Reactions
- Key Features and Benefits of neffy
- Supplemental Drug Application and Future Availability
- Understanding neffy
- Indication and Important Safety Information
- Recent Developments and Community Impact
- Expanding Access: Educational Initiatives
- Conclusion and Future Outlook
- Expanded Access to Epinephrine Nasal Spray Neffy Boosts Allergy Care for Millions
- Q&A Guide
- What is Neffy and How Does It Work?
- How Can Neffy Benefit Allergy Sufferers?
- What does the Expansion mean for Patients?
- what Is the Demand for Neffy in the Allergy Community?
- What Support and Education Programs does ARS Pharma Offer?
- What Future Developments Are Expected for Neffy?
- Conclusion: Ensuring Preparedness for Allergy Reactions
- Q&A Guide
, by News Directory 3.com
SAN DIEGO – ARS Pharmaceuticals, Inc. has announced a significant milestone in allergy care with the inclusion of their innovative epinephrine nasal spray, neffy®, on the national formularies of leading healthcare providers Cigna Healthcare, Navitus Health Systems, and OptumRx. This addition, five months after launch, has expanded access to neffy to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30.
Millions of patients nationwide now have improved access to neffy through their commercial insurance, thanks to coverage from leading pharmaceutical benefit managers and health plans. neffy will also be available at the lowest branded copay for patients insured by OptumRx, Cigna Healthcare, and Navitus Health Systems – without the need for prior authorizations or restrictive step therapies,
Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma, said. As a result, more patients will qualify for the low copay price of $25 for neffy, when they apply the ARS Pharma copay assistance, and healthcare providers can prescribe it without the need for additional paperwork.
The Critical Demand for Epinephrine Nasal Spray
This announcement underscores the critical demand for a nasal spray epinephrine option within the severe allergy community. While Emisar represents both OptumRx and UnitedHealthcare as their GPO, at present, only OptumRx has agreed to the Emisar terms. ARS Pharma is working closely with UnitedHealthcare, one of the country’s largest healthcare providers, to add neffy to their formulary as soon as possible.
Improved Coverage for Severe Allergic Reactions
The addition of neffy to these formularies improves coverage for the approximately 20 million people in the United States who have been diagnosed and treated for severe Type 1 allergic reactions. These conditions can often lead to anaphylaxis and necessitate epinephrine therapy for protection in daily life. To assist patients in navigating coverage and affordability challenges, ARS Pharma offers a series of support programs. More information is available on the ARS Pharma website.
Key Features and Benefits of neffy
As a needle-free alternative to traditional injectable epinephrine, neffy instructs two mg for the treatment of Type 1 Allergic Reactions. Its simple design ensures rapid administration, helping patients and caregivers react swiftly to emergencies. The product is easy to carry and has a shelf life of 30 months, withstanding high temperatures (up to 122 degrees Fahrenheit). Visit the neffy website for the full prescribing information.
Supplemental Drug Application and Future Availability
The supplemental NDA for neffy 1 mg for children over four years of age who weigh 15 to 30 kg, will be reviewed, with a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2024. Based on subject to approval, product availability is expected by the end of May 2024. ARS Pharma expects that by the epinephrine prescription renewal period, which occurs over the summer for many children in the United States, school-age children who meet the weight and age criteria, will have access to their resource.
Understanding neffy
neffy® is an intranasal epinephrine product for patients with Type 1 allergic reactions, including severe reactions to foods, medications, and insect bites, that could lead to life-threatening anaphylaxis.
Indication and Important Safety Information
neffy 2 mg is indicated for the emergency treatment of Type 1 allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. The recommended dosage is one spray in one nostril, repeated every 5 minutes if symptoms persist or worsen. For more information, visit the neffy website.
Contribute to your nasal health treatment program; the latest development focuses to propose clinician support and assist to educates caregivers on how to recognize and address the clinical trial avoids with
Recent Developments and Community Impact
neffy offers also a commitment to education and support. Community outreach programs, including educational materials and training sessions, rescue emergency/monitoring and epinephrine are being implemented in schools, businesses, and public spaces to ensure widespread understanding of this life-saving option for those at risk.
Expanding Access: Educational Initiatives
To promote safer allergy management, ARS Pharmaceuticals has initiated an extensive educational campaign. Educational sessions are being held in schools, summer camps, and various community events. The company plans to provide online resources, mobile applications, and a support hotline to guide patients. These initiatives aim to reduce the uncertainty surrounding allergy management and ensure that more Americans are prepared to handle emergency situations.
Conclusion and Future Outlook
The expansion of neffy availability on key formularies marks a significant step forward in treating life-threatening allergic reactions. With a commitment to education and support, ARS Pharmaceuticals is tackling the onset allergic reactions and a meaningful impact on the quality of life for millions of people across the United States. Future outlook includes ongoing collaborations with healthcare providers, educators, and community leaders to foster a well-informed and prepared population.
Expanded Access to Epinephrine Nasal Spray Neffy Boosts Allergy Care for Millions
Q&A Guide
What is Neffy and How Does It Work?
Q: What is simpler to understand about Neffy’s function and usage for allergic reactions?
- A: Neffy is an epinephrine nasal spray designed to treat severe allergic reactions, including anaphylaxis, in patients aged four years and older who weigh at least 15 kg, and up to 30 kg for the specific lower dose formulation.It offers a needle-free, intranasal choice to traditional injectable epinephrine. users administer the spray by inserting it into one nostril, and if symptoms persist, it can be repeated every 5 minutes. this easy-to-use format ensures swift response during allergic emergencies. For more detailed information, visit the Neffy medication guide ([1]) or the RxList page on Neffy ([3]).
How Can Neffy Benefit Allergy Sufferers?
Q: What are the key benefits of using Neffy for managing severe allergic reactions?
- A: Neffy offers several advantages:
– Rapid administration and ease of use make it suitable for emergency situations.
– Maintains a long shelf life of 30 months and can withstand temperatures of up to 122°F, making it highly portable.
– Collaboration with leading healthcare providers like Cigna Healthcare, Navitus Health Systems, and OptumRx expanded formulary access, allowing more patients to receive it at a low copay without prior authorization, supported by revenue management tools.
What does the Expansion mean for Patients?
Q: how does the expanded formulary inclusion of Neffy affect patients with allergies?
- A: The inclusion of Neffy on national formularies, covering 30 platforms as of February 20, 2024, means:
– Greater coverage thru commercial insurance for millions of patients with allergies.
– Reduced out-of-pocket costs, with the possibility of a $25 branded copay through specific insurers.
– Simplified prescribing process for healthcare providers, eliminating cumbersome paperwork.
– ARS Pharma offers support programs to address coverage and affordability issues.
what Is the Demand for Neffy in the Allergy Community?
Q: Why is there a high demand for an epinephrine nasal spray like Neffy?
- A: There is a critical need in the allergy community for alternatives like Neffy due to:
– Its needle-free,discrete administration method appeals to those hesitant about injectable epinephrine.
– The product fills a gap in accessibility and ease of use for timely treatment of severe reactions.
– Ongoing efforts to incorporate Neffy into more health plan formularies, including ongoing discussions with UnitedHealthcare, highlight this demand.
What Support and Education Programs does ARS Pharma Offer?
Q: What educational and support initiatives does ARS Pharma provide to promote Neffy usage?
- A: ARS Pharma’s outreach includes:
– Educational materials and training sessions in schools, businesses, and public spaces.
– Online resources and mobile applications aimed at reducing uncertainty in allergy management.
– A support hotline, enhancing community awareness and preparedness for allergic emergencies.
– The company’s commitment to fostering a knowledgeable and prepared user base ensures widespread adoption and effective use of Neffy.
What Future Developments Are Expected for Neffy?
Q: What future developments or availability updates are planned for Neffy?
- A: Key future plans for Neffy include:
– Review of the supplemental NDA for Neffy 1 mg, targeted for an action date by March 6, 2024, with expected availability by the end of May 2024.
– This will allow smaller children, aged four years and older weighing 15 to 30 kg, access to a dosage specifically tailored to their needs.
– Continued collaboration with healthcare providers, educators, and community leaders is predicted to enhance societal preparedness and further integrate Neffy into public health strategies.
Conclusion: Ensuring Preparedness for Allergy Reactions
Q: How notable is it for individuals to be prepared for severe allergic reactions, and how can neffy play a role?
- A: Preparing for allergy reactions is crucial for safety and confidence in managing potential anaphylaxis.Neffy’s widespread availability, backed by educational programs, ensures that individuals and caregivers can access and effectively use this life-saving medication. With ARS Pharma’s ongoing innovations and supportive initiatives, patients across the United States can better protect themselves and their families from life-threatening allergic emergencies. Stay informed and proactive in allergy management to enhance overall well-being and safety.
Note: Always consult healthcare professionals for personalized medical advice and dosage instructions.